Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Accumulated Expenses: 2009-2025

Historic Accumulated Expenses for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $61.6 million.

  • Cytokinetics' Accumulated Expenses rose 23.70% to $61.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.6 million, marking a year-over-year increase of 23.70%. This contributed to the annual value of $55.3 million for FY2024, which is 29.74% up from last year.
  • Cytokinetics' Accumulated Expenses amounted to $61.6 million in Q3 2025, which was up 17.81% from $52.3 million recorded in Q2 2025.
  • Cytokinetics' 5-year Accumulated Expenses high stood at $61.6 million for Q3 2025, and its period low was $14.8 million during Q1 2021.
  • Its 3-year average for Accumulated Expenses is $44.1 million, with a median of $42.6 million in 2023.
  • Per our database at Business Quant, Cytokinetics' Accumulated Expenses soared by 119.33% in 2021 and then fell by 18.08% in 2023.
  • Cytokinetics' Accumulated Expenses (Quarterly) stood at $34.4 million in 2021, then climbed by 28.30% to $44.1 million in 2022, then dropped by 3.30% to $42.6 million in 2023, then increased by 29.74% to $55.3 million in 2024, then climbed by 23.70% to $61.6 million in 2025.
  • Its last three reported values are $61.6 million in Q3 2025, $52.3 million for Q2 2025, and $43.4 million during Q1 2025.